NBD-556

Short Summary : HIV-1 entry inhibitor,CD4 mimetic,block gp120-CD4 interaction

Category : Microbiology & Virology|gp120/CD4

Purity : 0.98

CAS Number : 333353-44-9

Formula : C17H24ClN3O2

Molecular Weight : 337.84

SMILE : CC1(CC(CC(N1)(C)C)NC(=O)C(=O)NC2=CC=C(C=C2)Cl)C

Solubility : Soluble in DMSO

Storage : Store at -20°C

Description :
IC50: NBD-556 inhibited cellCcell fusion between H9/HIV-1IIIB and MT-2 (IC50 ~3 M)
The entry of HIV-1 into host cells is mediated by the binding of the surface subunit gp120 to the host cell receptor CD4. NBD-556 is a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitor that block the gp120CCD4 interaction with drug-like properties.
In vitro: A systematic study showed that NBD-556 and NBD-557 target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, protease, or integrase, demonstrating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection. NBD-556 and NBD-557 were also active against HIV-1 laboratory-adapted strains including an AZT-resistant strain and HIV-1 primary isolates, showing that these compounds can potentially be further modified to become potent HIV-1 entry inhibitors [1].
In vivo: No animal in-vivo data available currently.
Clinical trial: No clinical data are available.
Reference:[1] Zhao, Q. , L. Ma, S. Jiang, H. Lu, S. Liu, Y. He, N. Strick, N. Neamati, and A. K. Debnath. 2005. Identification of N-phenyl-N-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339:213-225.

Download datasheet